论文部分内容阅读
目的：探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组，每组30例，研究组口服氨磺必利治疗，对照组口服利培酮治疗。观察8周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗8周末，研究组显效率为70．0％、有效率为93．3％，对照组分别为66．7％、93．3％，两组比较差异无显著性（P＞0．05）。研究组锥体外系反应、肝功能异常及体质量增加发生率均显著低于对照组（P＜0．05）。结论氨磺必利治疗精神分裂症疗效显著且与利培酮相当，安全性高，依从性好。“,”Objective To explore the efficacy and safety of amisulpride vs .risper-idone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly divided into two groups of 30 ones each ,research group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse re-actions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week obvious effective and effective rate were respectively 70 .0% and 93 .3% in research and 66 .7% and 93 .3% in con-trol group ,which showed no significant differences (P> 0 .05) .Incidences of extrapyramidal reactions , dysfunction of liver and weight gain were significantly lower in research than in control group (P<0 .05) . Conclusion Amisulpride has an evident effect equivalent to risperidone ,higher safety and better compli-ance in the treatment of schizophrenia .